Belite Bio (NASDAQ:BLTE) Price Target Raised to $214.00

Belite Bio (NASDAQ:BLTE) had its price target boosted by HC Wainwright from $200.00 to $214.00 in a research note published on Wednesday, Marketbeat Ratings reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a report on Monday, July 6th. Zacks Research upgraded shares of Belite Bio from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 20th. Mizuho decreased their price target on shares of Belite Bio from $223.00 to $215.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 26th. Benchmark restated a “buy” rating on shares of Belite Bio in a research report on Friday, May 22nd. Finally, Truist Financial set a $217.00 price objective on shares of Belite Bio in a research note on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.80.

Belite Bio Stock Down 2.1%

BLTE opened at $162.80 on Wednesday. The company has a market cap of $6.53 billion, a PE ratio of -59.63 and a beta of -1.22. Belite Bio has a twelve month low of $60.00 and a twelve month high of $200.00. The company has a 50-day moving average price of $152.50 and a 200 day moving average price of $159.86.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.54) EPS for the quarter. As a group, sell-side analysts expect that Belite Bio will post -3.17 earnings per share for the current year.

Insiders Place Their Bets

In other Belite Bio news, insider Hendrik Peter Scholl sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $145.24, for a total transaction of $1,452,400.00. Following the sale, the insider owned 15,000 shares in the company, valued at $2,178,600. This represents a 40.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Hao-Yuan Chuang sold 367 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total value of $66,188.45. Following the completion of the sale, the chief financial officer directly owned 93,433 shares in the company, valued at $16,850,641.55. This represents a 0.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 20,732 shares of company stock worth $2,990,116 in the last quarter. 13.29% of the stock is owned by company insiders.

Institutional Trading of Belite Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of BLTE. Affinity Asset Advisors LLC increased its stake in Belite Bio by 225.0% in the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock valued at $10,364,000 after purchasing an additional 45,000 shares during the last quarter. Western Standard LLC acquired a new stake in Belite Bio during the fourth quarter worth approximately $9,602,000. The Manufacturers Life Insurance Company purchased a new position in shares of Belite Bio in the 1st quarter valued at $3,125,000. Renaissance Technologies LLC acquired a new stake in Belite Bio during the 1st quarter worth $8,291,000. Finally, Eventide Asset Management LLC lifted its position in Belite Bio by 96.1% in the fourth quarter. Eventide Asset Management LLC now owns 383,091 shares of the company’s stock valued at $61,279,000 after acquiring an additional 187,779 shares during the last quarter. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Belite Bio News Roundup

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.